10/19/2005 5:10:39 PM
Celltech Group plc (LSE:CCH) (NYSE:CLL) today announces that the European Medicines Evaluation Agency (EMEA) has accepted for review its marketing authorisation application for Xyrem (sodium oxybate) oral solution, a treatment for symptoms of narcolepsy. Xyrem has been filed through the EU centralised procedure, and has been granted Orphan Drug designation status in Europe, which provides a 10-year period of marketing exclusivity upon approval. Celltech will use its specialist sales forces to market the product to neurologists and sleep specialists across Europe following approval, anticipated during 2005.
comments powered by